161 related articles for article (PubMed ID: 35631364)
1. Design, Synthesis and Evaluation of Fused Bicyclo[2.2.2]octene as a Potential Core Scaffold for the Non-Covalent Inhibitors of SARS-CoV-2 3CL
Herlah B; Hoivik A; Jamšek L; Valjavec K; Yamamoto N; Hoshino T; Kranjc K; Perdih A
Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631364
[TBL] [Abstract][Full Text] [Related]
2. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
3. Discovery of highly potent covalent SARS-CoV-2 3CL
Zhang FM; Huang T; Wang F; Zhang GS; Liu D; Dai J; Zhang JW; Li QH; Lin GQ; Gao D; Zhao J; Tian P
Eur J Med Chem; 2023 Nov; 260():115721. PubMed ID: 37598484
[TBL] [Abstract][Full Text] [Related]
4. Identification of highly effective inhibitors against SARS-CoV-2 main protease: From virtual screening to in vitro study.
Wang H; Wen J; Yang Y; Liu H; Wang S; Ding X; Zhou C; Zhang X
Front Pharmacol; 2022; 13():1036208. PubMed ID: 36467060
[No Abstract] [Full Text] [Related]
5. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening.
Zhu W; Xu M; Chen CZ; Guo H; Shen M; Hu X; Shinn P; Klumpp-Thomas C; Michael SG; Zheng W
ACS Pharmacol Transl Sci; 2020 Oct; 3(5):1008-1016. PubMed ID: 33062953
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation.
Bepari AK; Reza HM
PeerJ; 2021; 9():e11261. PubMed ID: 33954055
[TBL] [Abstract][Full Text] [Related]
7. Structural similarities between SARS-CoV2 3CL
Bafna K; Cioffi CL; Krug RM; Montelione GT
Front Chem; 2022; 10():948553. PubMed ID: 36353143
[TBL] [Abstract][Full Text] [Related]
8. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
[TBL] [Abstract][Full Text] [Related]
9. Advances in research on 3C-like protease (3CL
Chen R; Gao Y; Liu H; Li H; Chen W; Ma J
RSC Med Chem; 2023 Jan; 14(1):9-21. PubMed ID: 36760740
[TBL] [Abstract][Full Text] [Related]
10. A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL
de Vries M; Mohamed AS; Prescott RA; Valero-Jimenez AM; Desvignes L; O'Connor R; Steppan C; Devlin JC; Ivanova E; Herrera A; Schinlever A; Loose P; Ruggles K; Koralov SB; Anderson AS; Binder J; Dittmann M
J Virol; 2021 Mar; 95(7):. PubMed ID: 33622961
[TBL] [Abstract][Full Text] [Related]
11. The SARS-CoV-2 main protease (M
Hu Q; Xiong Y; Zhu GH; Zhang YN; Zhang YW; Huang P; Ge GB
MedComm (2020); 2022 Sep; 3(3):e151. PubMed ID: 35845352
[TBL] [Abstract][Full Text] [Related]
12. Discovery and characterization of the covalent SARS-CoV-2 3CL
Zhang YN; Zhu GH; Liu W; Xiong Y; Hu Q; Zhuang XY; Jia GH; Zhang WD; Ge GB
Phytomedicine; 2023 Jun; 114():154796. PubMed ID: 37037086
[TBL] [Abstract][Full Text] [Related]
13. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.
Zhu W; Xu M; Chen CZ; Guo H; Shen M; Hu X; Shinn P; Klumpp-Thomas C; Michael SG; Zheng W
bioRxiv; 2020 Aug; ():. PubMed ID: 32803196
[TBL] [Abstract][Full Text] [Related]
14. Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CL
Guijarro-Real C; Plazas M; Rodríguez-Burruezo A; Prohens J; Fita A
Foods; 2021 Jun; 10(7):. PubMed ID: 34209659
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel 1,2,3-triazole isatin derivatives as potent SARS-CoV-2 3CLpro inhibitors
Jiang X; Li J; Viayna A; Luque FJ; Woodson M; Jing L; Gao S; Zhao F; Xie M; Toth K; Tavis J; Tollefson AE; Liu X; Zhan P
RSC Med Chem; 2023 Oct; 14(10):2068-2078. PubMed ID: 37859715
[TBL] [Abstract][Full Text] [Related]
16. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
Awoonor-Williams E; Abu-Saleh AAA
Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
[TBL] [Abstract][Full Text] [Related]
17.
Sharma A; Goyal S; Yadav AK; Kumar P; Gupta L
J Biomol Struct Dyn; 2022 Jan; 40(1):86-100. PubMed ID: 32896226
[TBL] [Abstract][Full Text] [Related]
18. Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen.
Kuzikov M; Costanzi E; Reinshagen J; Esposito F; Vangeel L; Wolf M; Ellinger B; Claussen C; Geisslinger G; Corona A; Iaconis D; Talarico C; Manelfi C; Cannalire R; Rossetti G; Gossen J; Albani S; Musiani F; Herzog K; Ye Y; Giabbai B; Demitri N; Jochmans D; Jonghe S; Rymenants J; Summa V; Tramontano E; Beccari AR; Leyssen P; Storici P; Neyts J; Gribbon P; Zaliani A
ACS Pharmacol Transl Sci; 2021 Jun; 4(3):1096-1110. PubMed ID: 35287429
[TBL] [Abstract][Full Text] [Related]
19. Plant Products as Inhibitors of Coronavirus 3CL Protease.
Mandal A; Jha AK; Hazra B
Front Pharmacol; 2021; 12():583387. PubMed ID: 33767619
[No Abstract] [Full Text] [Related]
20. Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.
Tomar S; Johnston ML; St John SE; Osswald HL; Nyalapatla PR; Paul LN; Ghosh AK; Denison MR; Mesecar AD
J Biol Chem; 2015 Aug; 290(32):19403-22. PubMed ID: 26055715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
